Prerpints.org logo
Preprint
Communication

Impacts of the Methylated Cyclodextrin KLEPTOSE® CRYSMEB on Inflammatory Responses in Human In Vitro Models

Altmetrics

Downloads

110

Views

85

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

22 April 2024

Posted:

24 April 2024

You are already at the latest version

Alerts
Abstract
KLEPTOSE® CRYSMEB is a methylated cyclodextrin derivative displaying less methylated group substitution than randomly methylated cyclodextrin. It has demonstrated an impact on atherosclerosis and neurological diseases. linked in part to cholesterol complexation and immune response, but the impact on inflammatory cascade pathways was not clear. Thus, the impact of KLEPTOSE® CRYSMEB on various pharmacological targets was assessed using human umbilical vein endothelial cells in physiological and inflammatory conditions, followed by screening against twelve human primary cell-based systems designed to model complex human tissue and disease biology of the vasculature, skin, lung, and inflammatory tissues using the BioMAP® Diversity PLUS® Panel. Finally, the anti-inflammatory mechanism was investigated on peripheral blood mononuclear cells to evaluate anti-inflammatory or pro-resolving properties. The results showed that KLEPTOSE® CRYSMEB can modulate the immune system in vitro and potentially manage vascular issues by stimulating the expression of molecules involved in the crosstalk between immune cells and other cell types. It showed anti-inflammatory effects driven by pro-inflammatory cytokine secretion inhibition and could have different impacts on different tissue types. Moreover, this cyclodextrin showed no clear impact on pro-resolving lipid mediators. Finally, it appeared that the mechanism of action of KLEPTOSE® CRYSMEB seems to not be shared by well-known anti-inflammatory molecules.
Keywords: 
Subject: Medicine and Pharmacology  -   Immunology and Allergy

1. Introduction

Inflammation is a natural response of the body following external stress. It is a response of the immune system that is induced by various stimuli, especially pathogens, toxins, lesions, etc... Many diseases involve inflammatory mechanisms such as autoimmune diseases, certain cancers, some neurological disorders, rheumatoid arthritis, bowel, and cardiovascular diseases [1,2]. The first aim of the inflammatory response is to eliminate or minimize the impact of infection or injury. After an acute inflammatory response, immune cells and different molecular events are involved in different interactions to restore tissue homeostasis, resolve the acute process, and induce regeneration [3]. However, the uncontrolled acute inflammatory response can induce chronic inflammation, which can contribute to a variety of chronic inflammatory diseases [4].
Many drugs are used to help control and resolve inflammatory responses. Amongst these, there are two major types of widely used anti-inflammatory drugs; corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs). Corticosteroids are used to treat chronic inflammatory diseases such as autoimmune diseases, asthma, and rheumatic arthritis. They suppress the various inflammatory genes activated in chronic inflammatory diseases: cytokines, chemokines, adhesion molecules, inflammatory enzymes, receptors, and others [5]. NSAIDs are widely used for their analgesic, anti-inflammatory, and anti-pyretic effects, and are amongst the most prescribed class of medications, representing approximately 5–10% of all medications prescribed each year [6]. They inhibit the cyclooxygenase (COX) enzymes and subsequently induce a decrease in different anti-inflammatory mediators such as prostaglandins [7]. However, the use of these two anti-inflammatory drug classes has significant disadvantages: corticosteroids can cause long-term adverse effects like hypertension, metabolic disorders, or gastric ulcers [8] and NSAIDs, although they act effectively during the acute inflammation phase, are not curative and their chronic use could lead to adverse effects, especially at gastric, renal, and hepatic levels [9]. Moreover, the efficacy of these two anti-inflammatory drug families diminishes along the application time.
Cyclodextrins (CDs) are cyclic glucose chain oligomers that are made up of different numbers of α-1-4-linked glucose residues and they present a cone-like cavity into which compounds like active ingredients, cholesterol, and derivatives may enter to form a water-soluble complex [10]. Cyclodextrins derived from native β-cyclodextrins (β-CD) show different biological and physical properties, mainly depending on their degree of substitution. Among these cyclodextrin derivatives, a particular methylated cyclodextrin differs from the randomly methylated β-CD (RAMEB): KLEPTOSE® CRYSMEB displaying less methylated group substitution than RAMEB.
Atherosclerosis is an inflammatory disease that is linked to high blood concentrations of small dense low-density lipoprotein cholesterol (sdLDL-C) [11]. Therapies using cyclodextrin (e.g. KLEPTOSE® CRYSMEB) as a cholesterol-sequestrating agent have demonstrated an impact in atherosclerosis [12]. Moreover, the inflammatory response in atherosclerosis was investigated with KLEPTOSE® CRYSMEB, where the authors demonstrated that T lymphocyte content was reduced in atherosclerotic plaques with the mode of action being immunomodulation and Th1 polarization [13]. In addition, other cyclodextrins such as hydroxypropyl β-cyclodextrin (HPβ-CD) were able to inhibit atherosclerosis, not only by increasing the efflux of cholesterol, but by involving anti-inflammatory mechanisms [14]. They can also induce atherosclerosis regression via macrophage reprogramming to improve cholesterol efflux and exert anti-inflammatory effects [15]. In addition, HPβ-CD and α-CD inhibited cholesterol crystal formation and the activation of complement on monocytes, and HPβ-CD reduced the Immunoglobulin G (IgG) deposition [16,17]. This anti-inflammatory effect of CDs is linked to a specific effect against cholesterol crystals [14]. Moreover, CDs may potentially be useful as active agents for the treatment of neurological disorders: first for diseases involving cholesterol depletion such as Niemann Pick type C disease and second, as anti-aggregative effect compounds for amyloid-related disorders such as Alzheimer’s disease or α-synuclein in Parkinson’s disease [18]. However, this has yet to be fully evaluated as clinical testing for the treatment of Alzheimer’s disease is ongoing.
All of the effects induced by CDs were linked to cholesterol complexation. Nevertheless, the potential effect of these compounds and their potential impact on cellular metabolism, interactions between cells from different tissues, and pro- and anti-inflammatory cascade pathways was not clear.
In the present study, we investigated the impact of KLEPTOSE® CRYSMEB on various pharmacological targets using human umbilical vein endothelial cells (HUVEC) in physiologically normal and inflammatory conditions, followed by screening against a panel of twelve human primary cell-based systems designed to model complex human tissue and disease biology of the vasculature, skin, lung, and inflammatory tissues using the BioMAP® Diversity PLUS® Panel. Finally, the anti-inflammatory mechanism of KLEPTOSE® CRYSMEB was investigated on peripheral blood mononuclear cells (PBMC) to evaluate anti-inflammatory or pro-resolving properties.
Human umbilical vascular endothelial cells (HUVEC) were chosen as a first primary cell type model. Indeed, endothelial cells: (i) participate in immune-modulation through various processes such as chemokine secretion, co-stimulatory and co-inhibitory receptor expression, leukocyte recruitment, and phagocytic capabilities[19], (ii) are valuably placed as a first-line defense system to contribute to immune responses [19], and (iii) process exogenous peptides through HLA-DR after IFN-γ stimulation [20]. They were thus considered as a relevant model with which to specifically evaluate the effects of KLEPTOSE® CRYSMEB in a first-line immunomodulation screening strategy. In this method, cells were treated in the presence (“inflammatory condition”) or absence (“non-inflammatory condition”) of TNF-α or IFN-γ.
Human primary cell-based models within the BioMAP® Diversity PLUS® Panel represent a broad set of tissue and disease biology, including: vascular biology, adaptive and innate immune responses, respiratory biology, fibrosis, and skin-relevant biology [21,22]. The BioMAP® systems used in this study (Table 1) are constructed with one or more primary cell types pooled from three or more healthy human donors, with stimuli (such as cytokines or growth factors) added to stimulate relevant signaling networks that naturally occur in human tissues or under pathological conditions.
BioMAP® profiling creates a unique signature of changes in protein biomarker readouts when normalized to vehicle controls within individual system environments. Biomarker readouts [7,8,9,10,11,12,13,14,15,16,17] per system) are therapeutically and biologically relevant, are predictive of disease outcomes or specific drug effects, and have been validated using agents with known mechanisms of action [22,23]. These diverse readouts include cell surface receptors, cytokines, chemokines, matrix molecules, and enzymes. In total, the Diversity PLUS® Panel contains 148 biomarker readouts, which are measured quantitatively by immune-based methods that detect proteins (e.g., ELISA) or functional assays that measure proliferation and viability.
Vascular biology is modeled in both a Th1 (3C system) and a Th2 (4H system) inflammatory environment, as well as in a Th1 inflammatory state specific to arterial smooth muscle cells (CASM3C system). Additional systems recapitulate aspects of the systemic immune response including monocyte-driven Th1 inflammation (LPS system) or T cell stimulation (SAg system), chronic Th1 inflammation driven by macrophage activation (lMphg system), and the T cell-dependent activation of B cells that occurs in germinal centers (BT system). The BE3C system (Th1) and the BF4T system (Th2) represent airway inflammation of the lung, while the MyoF system models myofibroblast-lung tissue remodeling. Lastly, skin biology is addressed in the KF3CT system by modeling Th1 cutaneous inflammation and the HDF3CGF system by modeling wound healing [23,24].
The inflammation process is divided into three steps: initiation, amplification, and resolution, which in sum lead to the complete restoration of the initial state. When correctly controlled, inflammation is supposed to end and lead to the complete restoration of the targeted tissue. Various cell and biochemical effectors from innate and adaptive systems are involved throughout the process and tightly regulated. The metabolism of pro-inflammatory mediators into inactive compounds is not sufficient to allow the tissue to come back to the initial state. Resolution is an active process, involving specific mediators that are biologically active and can be monitored in a Peripheral Blood Mononuclear Cell model as biomarkers of homeostasis. These biomarkers are issued from omega-6 and omega-3 polyunsaturated fatty acid (PUFA) metabolism and are termed lipoxins, resolvins, maresins, and protectins, which are collectively referred to as SPMs (Specialized Pro-resolving Mediators) [25,26].

2. Materials and Methods

All tested samples were of pharmaceutically active substance quality: methylated cyclodextrin Crysmeb (KLEPTOSE® CRYSMEB) and Isosorbide (ISOSORBIDE C PHARMA®) were supplied by Roquette Frères (Lestrem, France).

2.1. HUVEC Immuno-Profiling

Primary human umbilical vein endothelial cells (HUVEC, PromoCell) (passage 4) were seeded at 5000 cells/well in 96-well plates in ECGM medium (PromoCell) supplemented with 2% FBS and grown for 4 days before adding KLEPTOSE® CRYSMEB or ISOSORBIDE C PHARMA® (a polyol used as a humectant and in medicine as an osmotic diuretic without known pharmacological effects) to the medium at non-cytotoxic concentrations of 2.5 mg/mL (evaluated by cell counts / well on a flow cytometer, data not shown). The cells were treated for 48 hours in the presence (“inflammatory condition”) or absence (“non-inflammatory condition”) of 10 ng/mL TNF-α or 20 ng/mL IFN-γ before multi-parametric immunostaining and flow cytometry analysis. Briefly, detached cells were immunolabelled in FACS buffer (PBS / BSA 1% / EDTA 2 mM) with the following antibodies directed against multiple targets for 30 minutes on ice (ICAM-1, GITRL, HLA-E, CD55, CD59, CD39, VCAM-1, E/Psel, HVEM, IFN-γR1, TNFR1, all purchased from BioLegend). Cells were analyzed by flow cytometry at day 2, on a BD FACS Canto II, configuration 4/2/2. One experiment was performed in triplicate for each condition.

2.2. Phenotypic Profiling in Human Primary Cell-Based BioMAP® Systems

Phenotypic profiling with the BioMAP® Diversity PLUS® Panel was conducted by Eurofins Discovery (USA) as described previously [21], with doses of KLEPTOSE® CRYSMEB of 1000 µg/mL, 500 µg/mL, 250 µg/mL, and 130 µg/mL
Human primary cells
All studies follow the guidelines for human subject research under United States HHS human subject regulations (45 CFR Part 46). Preparation and culture of primary human cell types and methods for the systems were as previously described [22]. All primary human cells used in this work were obtained via commercial sources, cultured according to the supplier’s recommendation, and used at early passage (≤P4) to minimize adaptation to cell culture conditions and to preserve physiological signaling responses. Furthermore, cells were pooled from multiple (three or more) donors in this study to minimize the effect of donor-to-donor variation.
Primary human cell types used in BioMAP® systems and their stimuli include the following: 3C System (HUVEC / IL-1β, TNF-α and IFN-γ), 4H System (HUVEC / IL-4 and histamine), LPS System (PBMC and HUVEC / LPS), SAg System (PBMC and HUVEC / TCR ligands), BT System (CD19+ B cells and PBMC / anti-IgM + TCR ligands), BE3C System (bronchial epithelial cells / IL-1β, TNF-α, and IFN-γ), BF4T System (bronchial epithelial cells and human dermal fibroblasts / TNF-α and IL-4), HDF3CGF System (human dermal fibroblasts / IL-1β, TNF-α, IFN-γ, EGF, basic-FGF, and PDGF-BB), KF3CT System (keratinocytes and dermal fibroblasts / IL-1β, TNF-α, and IFN-γ), CASM3C System (coronary artery smooth muscle cells / IL-1β, TNF-α, and IFN-γ), MyoF System (differentiated lung myofibroblasts / TNF-α, and TGF-β), /Mphg System (HUVEC and macrophages / TLR2 ligands). Concentrations of stimuli were as previously published [21]. Adherent cells were cultured to confluence prior to assay initiation. The numbers of lymphocytes used were as previously published. Assays were initiated by the addition of KLEPTOSE® CRYSMEB , followed by the addition of appropriate stimuli. Assay plates were then incubated at 37°C in 5% CO2 for 24 hours, or as otherwise indicated. KLEPTOSE® CRYSMEB solution prepared in DMSO (final concentration ≤ 0.1%) was added at the previously indicated concentrations 1 hour before stimulation and remained in culture for 24 hour or as otherwise indicated (48 hour - MyoF system; 72 hour- BT system soluble readouts; 168 hour - BT system secreted IgG). The MyoF system was stimulated for 48 hours, and the BT system was stimulated for either 72 hours (soluble readouts) or 7 days (secreted IgG). Cell proliferation was determined by Sulforhodamine B (SRB) assay for adherent cell types or AlamarBlue™ for PBMC and B cells. For proliferation assays, individual cell types were cultured at sub-confluence and were read at specific times for different primary cell types (48, 72, or 96 hours). After stimulation, plates and supernatants were harvested and biomarkers were measured by ELISA and other methodologies: the levels of biomarker endpoints were measured by ELISA as described [22,27,28]. Proliferation of PBMC (T cells) was quantified by AlamarBlue™ reduction and proliferation of adherent cell types was quantified by SRB staining [22]. The SRB assay was performed by staining cells with 0.1% sulforhodamine B after fixation with 10% TCA and reading of wells at 560 nm [22]. PBMC viability was assessed by adding AlamarBlue™ to PBMC that had been cultured for 24 hours in the presence of activators and compounds, and subsequent measurement of its reduction after 8 hours.
Each plate contained drug controls (e.g., legacy control test agent colchicine at 1.1 μM), negative controls (e.g., non-stimulated conditions), and vehicle controls (e.g., 0.1% DMSO) appropriate for each system.
Raw data values for each readout for KLEPTOSE® CRYSMEB were divided by the raw mean vehicle control and then log10-transformed as previously described [29]. Significance prediction envelopes (95%) calculated from historical controls were used to determine activity at each assay endpoint. Biomarker activities were considered modified when two or more consecutive concentrations changed in the same direction relative to the vehicle controls, were outside of the significance envelope, and had at least one concentration with an effect size >20% (|log10 ratio| > 0.1). The four concentration profiles were compared against the reference profile library generated by Eurofins Discovery (with over 4500 substances), with a correlation metric comprised of a combination of similarity metrics in addition to a Pearson’s correlation as previously described [22,29]. Cluster analysis (function similarity map) used the results of pairwise correlation analysis to project the “proximity” of agent profiles from multi-dimensional space into two dimensions. Profiles that are similar with a Pearson’s correlation coefficient (r) ≥ 0.7 are connected by lines.

2.3. Peripheral Blood Mononuclear Cell Model for Cytokine Secretion and Resolution Assays

Peripheral Blood Mononuclear Cells
Peripheral Blood Mononuclear Cells (PBMC) from healthy volunteers were obtained from l’Etablissement Français du Sang (EFS). After isolation, the PBMCs were frozen until use in experiments. Cell culture medium Macrophage-SFM (M-SFM) was purchased from Gibco. LPS from the Escherichia coli K12 strain was bought from Invivogen. Antibiotics, phorbol 12-myristate 13-acetate (PMA), and A23187 (calimycin) were bought from Millipore Sigma. Multipexed kits for cytokine quantification (IL-1ß, IL-10, and TNF-α) were bought from Millipore Sigma. Inhibitors (dexamethasone, ibuprofen, and paracetamol) were purchased from Millipore Sigma.
Cell Isolation and Culture
PBMCs were obtained from healthy blood donor buffy coats by a standard Ficoll-Hypaque gradient method. PBMCs were seeded in macrophage-SFM with antibiotics, at 37°C in a humidified atmosphere containing 5% CO2. PBMCs were exposed to compounds and inhibitors for 24 hr. Medium was then changed to perform the resolution assay.
Lipidomic Analysis for Resolution Assay
HBSS +/+ buffer was used for the resolution assay with renewal of the compounds and inhibitors. Cells were exposed to the inflammatory stimulus (PMA/A23187) for 1 hr. Culture supernatants were then collected for subsequent analysis of lipid mediators. The extraction protocol and LC-MS/MS analysis were performed as adapted from Le Faouder et al [26]. Briefly, samples were extracted using oasis HLB 96-well solid phase extraction (Waters). LC-MS/MS analysis was performed on a UHPLC system (EXION LC AD, SCIEX) coupled to a QTrap 6500+ MS (SCIEX) instrument equipped with electro-spray ionization operating in negative mode.
Cytokine Secretion Assay
PBMCs were incubated with KLEPTOSE® CRYSMEB for 24 hr in the presence of antibiotics. Culture medium with KLEPTOSE® CRYSMEB was then renewed, and the PBMCs were stimulated with LPS 1 µg/ml for 24 hr. The supernatants were then collected and frozen until analysis. Cytokines (IL-1β, IL-10, and TNF-α) were analyzed with a with a MILLIPLEX® Multiplex assay kit and measured on a Luminex MAGPIX® reader.
Statistical Evaluation
The results were evaluated by comparing the variance according to Student’s t-test.

3. Results

3.1. Results on HUVEC Immuno-Profiling

In vitro HUVEC profiling revealed that ISOSORBIDE C PHARMA® showed no impact on biomarker modulation under physiologically normal or inflammatory conditions. As a negative control, this demonstrated that the model was valid since isosorbide is known to have no pharmacological effects (Figure 1). Moreover, the immunostimulation of HUVEC alone, following a 48-hr treatment with the inflammatory cytokines TNF-α and IFN-γ, showed a marked increase of the immune-related markers HVAM, ICAM-1, HLA-1, HLA-E, and HLA-DR, showing that the model was thus valid for the inflammatory conditions used and HUVEC responses. KLEPTOSE® CRYSMEB elicited statistically significant modulation of key biomarkers towards increased levels of expression of some of the immune-related markers such as IFN-γR1, ICAM-1, HVEM, GITRL, HLA-E, HLA-1, and markers that are involved in vascular protection such as CD55 and CD39 (Figure 1). Levels of HLA-DR and CD59 were unaffected.

3.2. Results on Phenotypic Profiling in Human Primary Cell-Based BioMAP® Systems

KLEPTOSE® CRYSMEB profiling (Figure 2) at the indicated concentrations identified 16 modulated annotated readouts in the Diversity PLUS® Panel out of the 148 analyzed endpoints. No cytotoxicity was observed with KLEPTOSE® CRYSMEB at any of the concentrations tested in that study. KLEPTOSE® CRYSMEB was antiproliferative to human primary endothelial cells (at 1000 μg/mL, 500 μg/mL, 250 μg/mL, 130 μg/mL) and fibroblasts (at 1000 μg/mL).
KLEPTOSE® CRYSMEB impacted inflammation-related activities (decreased monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor alpha (TNF-α), prostaglandin E2 (PGE2); increased vascular cell adhesion molecule 1 (VCAM-1), interleukin 8 (IL-8), interleukin-1alpha (IL-1α); modulated eotaxin 3, immunomodulatory activities (decreased interleukin 6 (IL-6), interleukin 2 (IL-2); increased CD40), tissue remodeling activities (decreased plasminogen activator inhibitor-1 (PAI-1); increased TIMP metallopeptidase inhibitor 1 (TIMP-1), urokinase plasminogen activator receptor (uPAR), and decreased low-density lipoprotein receptor (LDLR), a cell surface receptor involved in cholesterol regulation that mediates endocytosis of low-density lipoprotein (LDL) (Figure 2).
A similarity search analysis against the whole BioMAP® reference database (Table 2) showed that the profile is most similar to that of VX-745 (when tested at 120 nM); the Pearson’s correlation coefficient between these two profiles is r = 0.540, which is below a pre-determined threshold of r = 0.700, meaning that there is no statistically significant mechanistic similarity. VX-745 is an inhibitor of p38 MAPK, with greater selectivity for p38α versus p38β. The top Similarity Search match for the profile of KLEPTOSE® CRYSMEB at the second highest concentration (500 μg/mL) was quinacrine dihydrochloride dihydrate (when tested at 1.1 μM). The Pearson’s correlation coefficient between these two profiles is r = 0.562, which is also below the threshold for statistically significant mechanistic similarity. Quinacrine dihydrochloride dihydrate is an inhibitor of phospholipase A2 (PLA2) that is used as an antimalarial and an anthelmintic agent. No Similarity Search matches were identified for KLEPTOSE® CRYSMEB above the threshold for mechanistic similarity at any of the tested concentrations. In a pairwise correlation analysis, KLEPTOSE® CRYSMEB clusters at all four concentrations with a Pearson’s correlation coefficient (r) ≥ 0.700, meaning the induced phenotype is maintained across the dilution range (Figure 3), a characteristic commonly observed in marketed drugs.

3.3. Results on PBMC Model for Cytokines and Resolution Assays

Cytokine quantification
KLEPTOSE® CRYSMEB impact on cytokine production was assessed on PBMC culture model stimulated by LPS 1 µg/ml. Figure 1 shows the quantification of IL-1β, IL-10, and TNF-α production (mean and SEM on three replicates). These results demonstrate that KLEPTOSE® CRYSMEB inhibited the secretion of the three cytokines, with a dose effect on IL-10 and TNF- α.
Preprints 104571 g004
Figure 4. Cytokine quantification. IL-1β, IL-10, and TNF-α were quantified in cell supernatants: mean +/- SEM (n=3) in pg/ml: control, LPS alone or with KLEPTOSE® CRYSMEB at three different doses.
Figure 4. Cytokine quantification. IL-1β, IL-10, and TNF-α were quantified in cell supernatants: mean +/- SEM (n=3) in pg/ml: control, LPS alone or with KLEPTOSE® CRYSMEB at three different doses.
Preprints 104571 g004
Lipid mediator quantification
KLEPTOSE® CRYSMEB capacities to modulate inflammatory and resolving lipid mediator production were investigated using PBMC stimulated by PMA/A23187. The secretion of 23 lipid mediators was quantified (Table 3). We observed that KLEPTOSE® CRYSMEB induced a significant activation of pro-inflammatory mediators (5-HETE intermediate mediator, as well as a strong activation of PGE2 and TXB2). Of note was that these activations were not dose-dependent. We also measured a significant increase in the production of pro-resolving 14-HDOHE and 17-HDOHE lipid intermediates, but no increase in SPM mediators by themselves. Interestingly, we also quantified that KLEPTOSE® CRYSMEB induced an increase in 15-HETE and 12-HETE production that showed an activation of the 12-LOX and 15-LOX pathways.

4. Discussion

Endothelial cells share common innate immune functions with macrophages such as cytokine secretion, antigen presentation, pathogen-associated molecular pattern (PAMP) sensing, or even phagocytosis. Their plasticity allows them to regulate immune surveillance over the different tissues of the organism [30].
Interestingly, we report here that KLEPTOSE® CRYSMEB can upregulate the expression of molecules that are involved in the crosstalk between immune cells and surrounding cells like endothelial cells. Indeed, the increase in HLA-1 expression elicited by this drug may be linked to immune cell recruitment, as HLA-1 signaling was reported to impact leukocyte tethering or neutrophil adherence for instance [30]. This finding is supported by the drug-induced increase of ICAM-1, a protein that is implicated in the firm adhesion of activated T cells to the endothelium and their trans-endothelial migration [32], and GITRL, a molecule that is also involved in cell adhesion / migration / activation of innate cells [33,34,35]. Furthermore, the increase of GITRL on the surface of HUVEC (Figure 1E) may potentially facilitate GITR / GITRL signaling, thus resulting in T cell activation and proliferation [36,37]. GITR interaction stimulates antiviral responses through enhanced TNF-α and IFN-γ production in vivo [38] and GITR is expressed on numerous activated immune cell types such as Treg, macrophages, and natural killer (NK) cells, giving the opportunity for KLEPTOSE® CRYSMEB to also interact with cells that are involved in mediating innate immunity [39]. To support this finding, we confirmed that HLA-E was constitutively expressed on endothelial cells, and it is well established that HLA-E and NK receptor interaction is crucial for NK cell activation [40,41]. Moreover, KLEPTOSE® CRYSMEB induced an increase in IFN-γR1. IFN-γ binds to IFN-γR1 with a very high affinity to induce signaling via the JAK / STAT pathway and is constitutively expressed on endothelial cells. KLEPTOSE® CRYSMEB induced an overexpression of this receptor, which can lead to stronger sensitization of cells to IFN-γ and can lead to better activation of these cells. IFN-γ is secreted by immune cells during the early phase of the immune response (NK, LT CD4 helper, and LT CD8), allowing dedicated antigen-presenting cells (e.g., dendritic cells, macrophages) to increase the presentation of peptides from pathogens on HLA class II molecules. Moreover, KLEPTOSE® CRYSMEB increased both HLA-E and GITRL, a mechanism that can probably serve to help the immune system to boost immunosurveillance upon infection [38]. Activation and proliferation of T cells can also be supported by HVEM expression in an HVEM / LIGHT receptor / ligand context [42].
This first body of data supports the fact that KLEPTOSE® CRYSMEB tends to stimulate the expression of endothelial cell markers triggering the recruitment, migration, co-stimulation, and activation of T cells and NK cells. However, it is also interesting to highlight vascular protection. Indeed, complement deposition at the cell surface level is a mechanism that is often used to protect the human body from pathogens by inducing a lysis that is specific to the pathogen’s membrane with a complement-dependent cytotoxicity [43]. Different pathways are involved in this system (classical, alternative, and lectin pathways) [44] and CD55 is ideally placed at the beginning of the process to inhibit the complement cascade deposition. Indeed, the increase of CD55 in HUVEC when treated with KLEPTOSE® CRYSMEB (Figure 1E) can protect endothelial cells from lysis by accelerating the degradation of C3 convertase, a central enzyme that regulates the complement cascade at the initial step, CD59 interfering only at the terminal step (preventing the formation of Membrane Attack Complex C5b9) [45].
Another way to protect endothelial cells from injuries is to modulate platelet aggregation, a natural mechanism that occurs during bleeding. Interestingly, KLEPTOSE® CRYSMEB demonstrated the capability to increase levels of CD39, an endopeptidase that prevents excessive platelet aggregation and vascular leakage [46,47]. Moreover, CD39 is also described as a new immunomodulatory protein and is compared now with a new checkpoint inhibitor [48], a dual role that can very well illustrate KLEPTOSE® CRYSMEB bioactivity in vascular cells.
Montecucco et al [12] showed that KLEPTOSE® CRYSMEB has an impact on atherosclerosis in mouse models of disease. In this disease, platelet accumulation induces the recruitment of inflammatory cells towards the lesion sites [49]. The impact of KLEPTOSE® CRYSMEB on different markers and pathways that are involved in the modulation of platelet aggregation, preventing excessive platelet aggregation, cell lysis, and vascular leakage, could explain in part the observed in vivo impact of this cyclodextrin on atherosclerosis.
The first screening strategy using a primary endothelial cell model (HUVEC) demonstrated the potential of KLEPTOSE® CRYSMEB in vitro to modulate the immune system and to potentially manage vascular issues.
These impacts of KLEPTOSE® CRYSMEB on cellular interactions between immune cells and vascular cells, as well as other cells such as those from respiratory, muscle, and skin tissues, were elucidated using phenotypic profiling in human primary cell based BioMAP® systems. The observed decrease in prostaglandin E2 (PGE2) in the LPS system, which models monocyte activation, is shared by KLEPTOSE® CRYSMEB and several NSAIDs when tested in this platform. This activity is a sentinel biomarker for COX inhibition and suggests KLEPTOSE® CRYSMEB to have similar anti-inflammatory properties. Furthermore, KLEPTOSE® CRYSMEB treatment led to decreases in tissue inflammation and immunomodulatory biomarkers such as IL-2, IL-6, MCP-1, TNF-α. These effects on Th1 inflammation (LPS system) or the T cell-dependent activation of B cells that occurs in germinal centers (BT system) can be compared with the systemic effect of KLEPTOSE® CRYSMEB on Th1-mediated immunity that was observed in mice in an atherosclerotic context and in human T lymphocytes in vitro [12]. Indeed, KLEPTOSE® CRYSMEB dose-dependently inhibited the proliferation of Th1 CD4+ cells and methyl β-cyclodextrins can switch off the pro-inflammatory effects of IFN-γ on the vascular endothelium. The inhibition of Th1 immune responses has been described as a potential strategy to inhibit chronic inflammation and atherogenesis in mice [50,51]. Nevertheless, in the BioMAP® T cell activation model (T cell driven Th1 vascular inflammation model), no impact of KLEPTOSE® CRYSMEB on T cell proliferation was observed. Moreover, according to Montecucco et al [12], methyl β-cyclodextrins can modulate the immune response, switching off the pro-inflammatory effects of IFN-γ on the endothelium since IFN-γ can enhance the expression of adhesion molecules in endothelial cells that are needed for leukocyte–endothelial cell interaction. However, our results on human umbilical vein endothelial cells showed that KLEPTOSE® CRYSMEB induced an increase in IFN-γ receptors. So, the anti-inflammatory effects of KLEPTOSE® CRYSMEB seem to be driven by pro-inflammatory cytokine secretion inhibition and not at the cellular level on different receptors such as IFN-γR1, or on the expression of molecules that are involved in the crosstalk of immune cells and endothelial cells such as HLA-1, ICAM-1, GITRL.
In another way, some of the observed activities of KLEPTOSE® CRYSMEB are related to pro-inflammatory activities in the acute phase such as increased amounts of IL-8, which is a pro-inflammatory cytokine that is involved in the recruitment of neutrophils into acute inflammatory sites, as well as the increase of VCAM-1, a cell adhesion molecule that mediates the adhesion of monocytes and T cells into sites of inflammation. Eotaxin 3 was found to be context-dependently modulated: it was increased in a Th2-type vascular inflammation model (4H) but decreased in a Th2-type lung inflammation model (BF4T). Whilst the stimulation environments of these two systems are relatively similar, the cell types are different, suggesting that KLEPTOSE® CRYSMEB can have different impacts on different tissue types. Eotaxin-3 is a chemokine that mediates the recruitment of eosinophils and basophils into sites of tissue inflammation. This finding confirms the results on human umbilical vein endothelial cells regarding the impact of KLEPTOSE® CRYSMEB on the modulation on the expression of molecules that are involved in the crosstalk between immune and endothelial cells.
This effect of KLEPTOSE® CRYSMEB on immune responses seems to be at two distinct levels: affecting cytokine secretion and on the levels of cellular proteins that are involved with immune cell communication, recognition, etc.
A Similarity Search analysis against the whole BioMAP® reference database, with thousands of molecules and reference agents previously profiled, revealed no significantly similar profile matches, suggesting that the mechanism of action of KLEPTOSE® CRYSMEB is not shared with any molecule that has been tested as part of the reference database. This could potentially represent a unique mechanism of action, although the exact nature of that would need to be confirmed in a follow-up study of a more detailed mechanistic nature.
In addition, KLEPTOSE® CRYSMEB inhibited the secretion of IL-1β, IL-10, and TNF-α in PBMCs when stimulated by LPS. This suggests that this compound has anti-inflammatory capabilities. The mechanism of action of KLEPTOSE® CRYSMEB was then investigated by studying the inflammatory and resolving lipid mediator metabolism pathways on PBMCs when stimulated by PMA/A23187. Surprisingly, KLEPTOSE® CRYSMEB activated the COX enzyme as well as the 5-LOX, 12-LOX, and 15-LOX pathways, and induced an increase in pro-inflammatory mediators (metabolic pathway modulations corresponding to these results are represented in Figure 6). This result observed with PBMCs alone is the opposite of the one found with the BioMAP® LPS system, with which a diminution of PGE2 levels was observed. However, various experimental conditions in those studies were different and could explain this apparent contradiction: first, the stimulation used was PMA/A23187 (versus LPS), which induces a much stronger inflammatory response. Then, the lipid mediators were measured at 1 hr after PMA/A23187 stimulation (versus at 48 hr and 24 hr for the assays in HUVECs and 24, 48;72 or 168 hours in BioMAP® models respectively), and finally, the PBMCs were not in contact with HUVECs (as was the case in the BioMAP® system). KLEPTOSE® CRYSMEB could indeed demonstrate a better efficacy at a later time point and also on milder inflammation (as is the case with LPS stimulation). Additionally, the presence of vascular endothelial cells could influence the response to KLEPTOSE® CRYSMEB exposure and the impact on the crosstalk between immune cells and other cell types.
Moreover, we did not observe production of specialized pro-resolving lipid mediators (SPM) despite the production of pro-resolving lipid intermediates such as 14-HDoHe and 17-HDoHe. One reason that could explain these observations is that inflammation is a kinetic process, characterized by the sequential production of pro-inflammatory and pro-resolving mediators. We thus suggest that the quantification of SPMs at other time points would allow for a better deciphering of the mechanisms of action of KLEPTOSE® CRYSMEB.
In addition, KLEPTOSE® CRYSMEB induced a decrease in low-density lipoprotein receptors, which are involved in cholesterol regulation. This is due to the well-known membrane cholesterol-extracting effect of cyclodextrins and derivatives on cholesterol levels and thus their impact on lipid raft disruption, as well as changes in biophysical parameters and organization of membrane bilayers, which can also induce an indirect modulation of protein function [17]. In summary, this also represents another facet of KLEPTOSE® CRYSMEB activity that would warrant further evaluation and potential confirmation in follow-up studies.

5. Conclusions

KLEPTOSE® CRYSMEB can modulate in vitro the immune system and potentially manage vascular issues by stimulating the expression of molecules involved in the crosstalk between immune cells and other cell types, especially for the recruitment, migration, co-stimulation, and activation of T cells and NK cells. KLEPTOSE® CRYSMEB showed anti-inflammatory effects driven by pro-inflammatory cytokine secretion inhibition and not at the cellular level on different receptors. So, the effect of KLEPTOSE® CRYSMEB on immune responses seems to be at two distinct levels: cytokine secretion and on proteins involved in communications with immune cells. Thus, this compound could have different impacts on different tissue types. Moreover, KLEPTOSE® CRYSMEB showed no clear impact on pro-resolving lipid mediators. Finally, it appears that the mechanism of action of KLEPTOSE® CRYSMEB seems not to be shared with well-known anti-inflammatory molecules and further studies are needed to elucidate the detailed mechanistic nature of this, especially the interaction between immune cells and other cell types. Moreover, the kinetic aspects of these effects would be important to study to better dissect and characterize the mechanisms of action of KLEPTOSE® CRYSMEB.

Author Contributions

Conceptualization, Damien Truffin; methodology, Damien Truffin, Flora Marchand, Mathias Chatelais, Frauke Herbst, Justin Lipner, Alastair J. King; software, Flora Marchand, Mathias Chatelais, Frauke Herbst, Justin Lipner, Alastair J. King, ; validation, Damien Truffin, Flora Marchand, Mathias Chatelais, Frauke Herbst, Justin Lipner, Alastair J. King; formal analysis Damien Truffin, Flora Marchand, Mathias Chatelais, Frauke Herbst, Justin Lipner, Alastair J. King; investigation, Damien Truffin, Flora Marchand, Mathias Chatelais, Frauke Herbst, Justin Lipner, Alastair J. King; resources, Damien Truffin.; data curation, Damien Truffin, Flora Marchand, Mathias Chatelais, Frauke Herbst, Justin Lipner, Alastair J. King; writing—original draft preparation, Damien Truffin, Flora Marchand, Mathias Chatelais, Frauke Herbst, Justin Lipner, Alastair J. King; writing—review and editing, Damien Truffin, Flora Marchand, Mathias Chatelais, Frauke Herbst, Justin Lipner, Alastair J. King; visualization, Damien Truffin; supervision Damien Truffin.; project administration, Damien Truffin.; funding acquisition, Damien Truffin. All authors have read and agreed to the published version of the manuscript.”.

Funding

This research was funded by ROQUETTE. The funding sponsors had no role neither in the conduct, the monitoring of the study; nor in the collection, analysis or interpretation of the data.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data are not publicly available due to privacy.

Conflicts of Interest

Damien Truffin is employee of ROQUETTE.

References

  1. Chen, L., Deng H., Cui H., Fang J., Zuo Z., Deng J., Li Y., Wang X. and Zhao L. Inflammatory responses and inflammation-associated diseases in organs. 2018. Oncotarget. 23, 9, 7204–7218.
  2. Kinney J.W., Bemiller S.M., Murtishaw A. S., Leisgang A.M., Salazar M. A. and Lamb T. B. Inflammation as a central mechanism in Alzheimer’s disease. 2018. Alzheimers Dement (N Y). 4, 575–590.
  3. Abdulkhaleq, L.A.; Assi, M.A.; Abdullah, R.; Zamri-Saad, M.; Taufiq-Yap, Y.H.; Hezmee, M.N.M. The crucial roles of inflammatory mediators in inflammation: A review. Veter- World 2018, 11, 627–635. [Google Scholar] [CrossRef] [PubMed]
  4. Zhou Y, Hong Y, Huang H. Triptolide Attenuates Inflammatory Response in Membranous Glomerulo-Nephritis Rat via Downregulation of NF-κB Signaling Pathway. 2016. Kidney and Blood Pressure Res. 41, 901–910.
  5. Barnes, P.J. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br. J. Pharmacol. 2006, 148, 245–254. [Google Scholar] [CrossRef] [PubMed]
  6. Abdu, N.; Mosazghi, A.; Teweldemedhin, S.; Asfaha, L.; Teshale, M.; Kibreab, M.; Anand, I.S.; Tesfamariam, E.H.; Russom, M. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Usage and co-prescription with other potentially interacting drugs in elderly: A cross-sectional study. PLOS ONE 2020, 15, e0238868. [Google Scholar] [CrossRef] [PubMed]
  7. Matsui, H.; Shimokawa, O.; Kaneko, T.; Nagano, Y.; Rai, K.; Hyodo, I. The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine. J. Clin. Biochem. Nutr. 2011, 48, 107–111. [Google Scholar] [CrossRef] [PubMed]
  8. Rice, J.B.; White, A.G.; Scarpati, L.M.; Wan, G.; Nelson, W.W. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clin. Ther. 2017, 39, 2216–2229. [Google Scholar] [CrossRef] [PubMed]
  9. Ghlichloo I. and Gerriets V. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).2023. StatPearls. Available online: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls - NCBI Bookshelf (nih.gov) (accessed on 24 october 2023).
  10. Gould, S., Scott R.C. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. 2005. Food Chem Toxicol. 43, 10, 1451-9.
  11. Arai, H.; Kokubo, Y.; Watanabe, M.; Sawamura, T.; Ito, Y.; Minagawa, A.; Okamura, T.; Miyamato, Y. Small Dense Low-Density Lipoproteins Cholesterol can Predict Incident Cardiovascular Disease in an Urban Japanese Cohort: The Suita Study. J. Atheroscler. Thromb. 2013, 20, 195–203. [Google Scholar] [CrossRef] [PubMed]
  12. Coisne, C.; Tilloy, S.; Monflier, E.; Wils, D.; Fenart, L.; Gosselet, F. Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases. Molecules 2016, 21, 1748. [Google Scholar] [CrossRef]
  13. Montecucco, F.; Lenglet, S.; Carbone, F.; Boero, S.; Pelli, G.; Burger, F.; Roth, A.; Bertolotto, M.; Nencioni, A.; Cea, M.; et al. Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. Vasc. Pharmacol. 2015, 72, 197–208. [Google Scholar] [CrossRef] [PubMed]
  14. Appleton, S.L.; Navarro-Orcajada, S.; Martínez-Navarro, F.J.; Caldera, F.; López-Nicolás, J.M.; Trotta, F.; Matencio, A. Cyclodextrins as Anti-inflammatory Agents: Basis, Drugs and Perspectives. Biomolecules 2021, 11, 1384. [Google Scholar] [CrossRef]
  15. Zimmer, S.; Grebe, A.; Bakke, S.S.; Bode, N.; Halvorsen, B.; Ulas, T.; Skjelland, M.; De Nardo, D.; Labzin, L.I.; Kerksiek, A.; et al. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci. Transl. Med. 2016, 8, 333ra50–333ra50. [Google Scholar] [CrossRef]
  16. Bakke, S.S.; Aune, M.H.; Niyonzima, N.; Pilely, K.; Ryan, L.; Skjelland, M.; Garred, P.; Aukrust, P.; Halvorsen, B.; Latz, E.; et al. Cyclodextrin Reduces Cholesterol Crystal–Induced Inflammation by Modulating Complement Activation. J. Immunol. 2017, 199, 2910–2920. [Google Scholar] [CrossRef]
  17. Pilely, K.; Bakke, S.S.; Palarasah, Y.; Skjoedt, M.-O.; Bartels, E.D.; Espevik, T.; Garred, P. Alpha-cyclodextrin inhibits cholesterol crystal-induced complement-mediated inflammation: A potential new compound for treatment of atherosclerosis. Atherosclerosis 2019, 283, 35–42. [Google Scholar] [CrossRef] [PubMed]
  18. Kovacs, T.; Nagy, P.; Panyi, G.; Szente, L.; Varga, Z.; Zakany, F. Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates? Pharmaceutics 2022, 14, 2559. [Google Scholar] [CrossRef] [PubMed]
  19. Amersfoort, J.; Eelen, G.; Carmeliet, P. Immunomodulation by endothelial cells — partnering up with the immune system? Nat. Rev. Immunol. 2022, 22, 576–588. [Google Scholar] [CrossRef]
  20. Maenaka, A., Kenta I., Ota A., Miwa Y., Ohashi W., Horimi K., Matsuoka Y., Ohnishi M., Uchida K., Kobayashi T. Interferon-γ-induced HLA Class II expression on endothelial cells is decreased by inhibition of mTOR and HMG-CoA reductase. 2020. FEBS Open Bio. 10, 927–36.
  21. Shah, F.; Stepan, A.F.; O’Mahony, A.; Velichko, S.; Folias, A.E.; Houle, C.; Shaffer, C.L.; Marcek, J.; Whritenour, J.; Stanton, R.; et al. Mechanisms of Skin Toxicity Associated with Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators. Cell Chem. Biol. 2017, 24, 858–869. [Google Scholar] [CrossRef] [PubMed]
  22. Berg, E.L.; Yang, J.; Melrose, J.; Nguyen, D.; Privat, S.; Rosler, E.; Kunkel, E.J.; Ekins, S. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J. Pharmacol. Toxicol. Methods 2010, 61, 3–15. [Google Scholar] [CrossRef]
  23. Kunkel, E.J., Dea M., Ebens A., Hytopoulos E., Melrose J., Nguyen D., Ota K.S., Plavec I.,, Watson S.R., Butcher E.C., Berg E.L. An integrative biology approach for analysis of drug action in models of human vascular inflammation. 2004. The FASEB Journal. 18, 11, 1279-1281.
  24. Kunkel, E.J., Plavec I., Nguyen D., Melrose J., Rosler E.S., Kao L.T., Wang Y., Hytopoulos E., Anthony C. Bishop, R. Bateman, K. Shokat, Butcher E.C., Berg E.L. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. 2004. Assay Drug Development Technologies. 2, 4, 431-442.
  25. G. Zhang, X. Liu, C. Wang, L. Qu, J. Deng, H. Wang, Z. Qin. Resolution of PMA-Induced Skin Inflammation Involves Interaction of IFN- and ALOX15. 2013. Mediators of Inflammation. 1-11.
  26. Le Faouder, P.; Baillif, V.; Spreadbury, I.; Motta, J.-P.; Rousset, P.; Chêne, G.; Guigné, C.; Tercé, F.; Vanner, S.; Vergnolle, N.; et al. LC–MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites. J. Chromatogr. B 2013, 932, 123–133. [Google Scholar] [CrossRef]
  27. Xu, D., Kim Y., Postelnek J., Vu M.D., Hu D.Q., Liao C., Bradshaw M., Hsu J., Zhang J., Pashine A., Srinivasan D., Woods J., Levin A., O’Mahony A., Owens T.D., Lou Y., Hill R.J., Narula S., DeMartino J., Fine J.S. RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. 2012. J. Pharmacol. Exp. Ther. 341,1, 90-103.
  28. Melton, A.C.; Melrose, J.; Alajoki, L.; Privat, S.; Cho, H.; Brown, N.; Plavec, A.M.; Nguyen, D.; Johnston, E.D.; Yang, J.; et al. Regulation of IL-17A Production Is Distinct from IL-17F in a Primary Human Cell Co-culture Model of T Cell-Mediated B Cell Activation. PLOS ONE 2013, 8, e58966. [Google Scholar] [CrossRef]
  29. Houck, K.A., Dix D.J., Judson R.S., Kavlock R.J., Yang J., Berg E.L. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. 2009. Journal of Biomolecular Screening. 14, 9, 1054-1066.
  30. Shao, Y., Saredy J., Yang W.Y., Sun Y., Lu Y., Saaoud F., Drummer C., Johnson C., Xu K., Jiang X., Wang H., Yang X. Vascular Endothelial Cells and Innate Immunity. 2020 Arterioscler Thromb Vasc Biol. 40, 138–152.
  31. Valenzuela, N.M., Reed E.F. Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft Injury. 2015. Curr Transplant Rep. 2, 222–32.
  32. Lehmann, J.C.U.; Jablonski-Westrich, D.; Haubold, U.; Gutierrez-Ramos, J.-C.; Springer, T.; Hamann, A. Overlapping and Selective Roles of Endothelial Intercellular Adhesion Molecule-1 (ICAM-1) and ICAM-2 in Lymphocyte Trafficking. J. Immunol. 2003, 171, 2588–2593. [Google Scholar] [CrossRef]
  33. Nocentini, G., Riccardi C. GITR: a modulator of immune response and inflammation. 2009. Adv Exp Med Biol. 647,156-73.
  34. Shimizu, J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(þ)CD4(þ) regulatory T cells through GITR breaks immunological self-tolerance. 2002. Nat Immunol. 3, 135-42.
  35. McHugh, R.S.; Whitters, M.J.; A Piccirillo, C.; A Young, D.; Shevach, E.M.; Collins, M.; Byrne, M.C. CD4+CD25+ Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor. Immunity 2002, 16, 311–323. [Google Scholar] [CrossRef]
  36. Tian, J., Zhang B., Rui K., Wang S. The Role of GITR/GITRL Interaction in Autoimmune Diseases. 2020. Front Immunol. 11, 588682.
  37. Nocentini, G.; Riccardi, C. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur. J. Immunol. 2005, 35, 1016–1022. [Google Scholar] [CrossRef] [PubMed]
  38. Dittmer, U.; He, H.; Messer, R.J.; Schimmer, S.; Olbrich, A.R.; Ohlen, C.; Greenberg, P.D.; Stromnes, I.M.; Iwashiro, M.; Sakaguchi, S.; et al. Functional Impairment of CD8+ T Cells by Regulatory T Cells during Persistent Retroviral Infection. Immunity 2004, 20, 293–303. [Google Scholar] [CrossRef] [PubMed]
  39. Clouthier, D.L.; Watts, T.H. Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection. Cytokine Growth Factor Rev. 2014, 25, 91–106. [Google Scholar] [CrossRef]
  40. Djaoud, Z.; Riou, R.; Gavlovsky, P.-J.; Mehlal, S.; Bressollette, C.; Gérard, N.; Gagne, K.; Charreau, B.; Retière, C. Cytomegalovirus-Infected Primary Endothelial Cells Trigger NKG2C+ Natural Killer Cells. J. Innate Immun. 2016, 8, 374–385. [Google Scholar] [CrossRef]
  41. Petrie, E.J.; Clements, C.S.; Lin, J.; Sullivan, L.C.; Johnson, D.; Huyton, T.; Heroux, A.; Hoare, H.L.; Beddoe, T.; Reid, H.H.; et al. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. J. Exp. Med. 2008, 205, 725–735. [Google Scholar] [CrossRef]
  42. Croft, M. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM–BTLA. Trends Immunol. 2005, 26, 292–294. [Google Scholar] [CrossRef]
  43. Kolev, M.; Towner, L.; Donev, R. Complement in Cancer and Cancer Immunotherapy. Arch. Immunol. et Ther. Exp. 2011, 59, 407–419. [Google Scholar] [CrossRef] [PubMed]
  44. Dho, S.H., Lim J.C., Kim L.K. Beyond the Role of CD55 as a Complement Component. 2018.Immune Network 18,-13.
  45. Kuraya M., Yefenof E., Klein G., Klein E. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis. 1992. Eur J Immunol. 22,1871–1876.
  46. Robson, S.C.; Kaczmarek, E.; Siegel, J.B.; Candinas, D.; Koziak, K.; Millan, M.; Hancock, W.W.; Bach, F.H. Loss of ATP Diphosphohydrolase Activity with Endothelial Cell Activation. J. Exp. Med. 1997, 185, 153–164. [Google Scholar] [CrossRef]
  47. Marcus, A.J.; Broekman, M.J.; Drosopoulos, J.H.F.; E Olson, K.; Islam, N.; Pinsky, D.J.; Levi, R. Role of CD39 (NTPDase-1) in Thromboregulation, Cerebroprotection, and Cardioprotection. Semin. Thromb. Hemost. 2005, 31, 234–246. [Google Scholar] [CrossRef]
  48. Allard, B.; Longhi, M.S.; Robson, S.C.; Stagg, J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol. Rev. 2017, 276, 121–144. [Google Scholar] [CrossRef]
  49. Lievens, D., Von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost. 2011, 106:5, 827-838.
  50. Hilgendorf, I.; Theurl, I.; Gerhardt, L.M.; Robbins, C.S.; Weber, G.F.; Gonen, A.; Iwamoto, Y.; Degousee, N.; Holderried, T.A.; Winter, C.; et al. Innate Response Activator B Cells Aggravate Atherosclerosis by Stimulating T Helper-1 Adaptive Immunity. Circulation 2014, 129, 1677–1687. [Google Scholar] [CrossRef] [PubMed]
  51. Li, N. CD4+ T cells in atherosclerosis: Regulation by platelets. Arthritis Res. Ther. 2013, 109, 980–990. [Google Scholar] [CrossRef] [PubMed]
Preprints 104571 g001
Figure 1. Immuno-profiling of HUVEC following treatment with KLEPTOSE® CRYSMEB and ISOSORBIDE C PHARMA® under physiologically normal and inflammatory conditions [A] [B]. Representative immunostimulatory protein responses, following a 48-hr treatment with the inflammatory cytokines TNF-α and IFN-γ [C]. Effect of KLEPTOSE® CRYSMEB on antigen presentation, cell recruitment [D], immunomodulation of co-stimulatory proteins and vasculo-protective markers [E]. Control-Med (medium alone), Control-TNF (TNF alone), and Control-IFN (IFN alone) unpaired t-test, two-tailed, ns : non-significant, p value: ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05.
Figure 1. Immuno-profiling of HUVEC following treatment with KLEPTOSE® CRYSMEB and ISOSORBIDE C PHARMA® under physiologically normal and inflammatory conditions [A] [B]. Representative immunostimulatory protein responses, following a 48-hr treatment with the inflammatory cytokines TNF-α and IFN-γ [C]. Effect of KLEPTOSE® CRYSMEB on antigen presentation, cell recruitment [D], immunomodulation of co-stimulatory proteins and vasculo-protective markers [E]. Control-Med (medium alone), Control-TNF (TNF alone), and Control-IFN (IFN alone) unpaired t-test, two-tailed, ns : non-significant, p value: ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05.
Preprints 104571 g001
Preprints 104571 g002
Figure 2. BioMAP® profile of KLEPTOSE® CRYSMEB in the Diversity PLUS® Panel. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The y-axis represents a log-transformed ratio of the biomarker readouts for the drug-treated sample (n = 1) over vehicle controls (n ≥ 6). The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Antiproliferative effects are indicated by a thick grey arrow.
Figure 2. BioMAP® profile of KLEPTOSE® CRYSMEB in the Diversity PLUS® Panel. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The y-axis represents a log-transformed ratio of the biomarker readouts for the drug-treated sample (n = 1) over vehicle controls (n ≥ 6). The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Antiproliferative effects are indicated by a thick grey arrow.
Preprints 104571 g002
Preprints 104571 g003
Figure 3. Cluster analysis (function similarity map) for KLEPTOSE® CRYSMEB. Each colored circle represents the BioMAP profile at a specific concentration, with larger circles representing higher concentrations. Profiles that are similar with a Pearson’s correlation coefficient (r) ≥ 0.700 are connected by lines.
Figure 3. Cluster analysis (function similarity map) for KLEPTOSE® CRYSMEB. Each colored circle represents the BioMAP profile at a specific concentration, with larger circles representing higher concentrations. Profiles that are similar with a Pearson’s correlation coefficient (r) ≥ 0.700 are connected by lines.
Preprints 104571 g003
Preprints 104571 g005
Figure 6. Summary of metabolic pathway modulation for ARA, DHA, EPA on PBMCs when exposed to KLEPTOSE® CRYSMEB.
Figure 6. Summary of metabolic pathway modulation for ARA, DHA, EPA on PBMCs when exposed to KLEPTOSE® CRYSMEB.
Preprints 104571 g005
Table 1. BioMAP® systems tested in this study.
Table 1. BioMAP® systems tested in this study.
Preprints 104571 i001
Table 2. KLEPTOSE® CRYSMEB Similarity Search analysis against the whole BioMAP® reference database of >4,500 test agents.
Table 2. KLEPTOSE® CRYSMEB Similarity Search analysis against the whole BioMAP® reference database of >4,500 test agents.
Preprints 104571 i002
Table 3. Pro-inflammatory and pro-resolving lipid mediators quantification. The table shows the mean values (n=3) for each lipid mediator in each studied condition in pg/ml: control, PMA/A23187 alone or with KLEPTOSE® CRYSMEB at 3 different doses. The presence of “-” indicates that the value wass under the limit of quantification (the limit of quantification is indicated at the bottom of each column). *data significance (p <0,05 to the control). Values in parentheses indicate the % of activation compared with PMA/A23187 stimulation. These values are calculated based on the mean values. A. Metabolites originating from arachidonic acid (ARA) metabolism, B. Metabolites originating from docosahexaenoic acid (DHA) metabolism, C. Metabolites originating from eicosapentaenoic acid (EPA) metabolism.
Table 3. Pro-inflammatory and pro-resolving lipid mediators quantification. The table shows the mean values (n=3) for each lipid mediator in each studied condition in pg/ml: control, PMA/A23187 alone or with KLEPTOSE® CRYSMEB at 3 different doses. The presence of “-” indicates that the value wass under the limit of quantification (the limit of quantification is indicated at the bottom of each column). *data significance (p <0,05 to the control). Values in parentheses indicate the % of activation compared with PMA/A23187 stimulation. These values are calculated based on the mean values. A. Metabolites originating from arachidonic acid (ARA) metabolism, B. Metabolites originating from docosahexaenoic acid (DHA) metabolism, C. Metabolites originating from eicosapentaenoic acid (EPA) metabolism.
A; ARA metabolites (% activation of PMA/A23187)
Mean n=3 (pg/ml) Inflammatory mediators : SPM :
Doses (mg/mL) Stimulation PGE2 6K-PGF1A TXB2 LTB4 5-HETE 12-HETE 15-HETE LXA4 LXB4
Control 0 No 1.17 * - 7.99 * 4.61 6.73 * 135.47 * 10.94 * 1.14 * 0.0125 *
(-93.3) - (-98.4) (-100.0) (-99.9) (-99.5) (-96.9) (-86.6) (-99.9)
Control 0 Yes 17.56 - 502.97 12 488.17 10 061.78 28 236.36 355.95 8.50 10.42
(0.0) - (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0)
CRYSMEB 0.625 Yes 50.97 * - 2465.47 * 13 852.19 12709.66 * 42393.25 * 790.23 * 6.57 * 11.51
(190.2) - (390.2) (10.9) (26.3) (50.1) (122.0) (-22.7) (10.5)
CRYSMEB 1.25 Yes 222.70 - 4 735.65 14 612.74 17096.85 * 49679.45 * 1036.83 * 7.10 6.55
(1168.2) - (841.5) (17.0) (69.9) (75.9) (191.3) (-16.5) (-37.1)
CRYSMEB 2.5 Yes 113.47 * - 3357.35 * 10 047.64 13 621.02 46766.97 * 972.6 * 4.13 * 5.46
(546.1) - (567.5) (-19.5) (35.4) (65.6) (173.2) (-51.5) (-47.6)
LOQ(pg/mL) 0.313 5.000 0.625 0.625 0.625 1.250 1.250 0.156 1.250
B; DHA metabolites (% activation of PMA/A23187 control)
Mean n=3 (pg/ml) Intermediate
mediators : 		SPM :
Doses (mg/mL) Stimulation 14-HDOHE 17-HDOHE 7(R)-MAR1 MAR2 PDX PD1 RVD1 RVD2 RVD3 RVD4 RVD5
Control 0 No 38.65 * 11.41 * - 0.06 * - - - - 0.91 0.85 0.23 *
(-96.3) (-85.2) - (-96.9) - - - - (-19.2) (-16.1) (-95.9)
Control 0 Yes 1 054.67 77.28 - 1.84 - - - - 1.13 1.01 5.63
(0.0) (0.0) - (0.0) - - - - (0.0) (0.0) (0.0)
CRYSMEB 0.625 Yes 1848.19 * 148.6 * 0.92 * 1.27 * - - - - 1.15 0.98 6.59
(75.2) (92.3) - (-30.8) - - - - (2.0) (-2.9) (17.0)
CRYSMEB 1.25 Yes 2070.57 * 152.1 * 0.97 * 1.1 * - - - - 0.6 * 0.81 7.13
(96.3) (96.8) - (-40.2) - - - - (-46.8) (-19.8) (26.6)
CRYSMEB 2.5 Yes 1997.09 * 165.85 * 0.69 1.05 * - - - - 0.84 0.53 * 5.20
(89.4) (114.6) - (-42.7) - - - - (-25.6) (-47.4) (-7.6)
LOQ (pg/mL) 1.250 2.500 0.313 0.156 0.313 0.313 0.625 0.625 0.156 0.156 0.625
C; EPA metabolites (% activation of PMA/A23187)
Mean n=3 (pg/ml) Intermediate
mediators : 		SPM :
Doses (mg/mL) Stimulation 18-HEPE RVE1 RVE2
Control 0 No 6,75 * 3,95 7,50
(-44,7) (17,2) (-8,8)
Control 0 Yes 12,21 3,37 8,23
(0,0) (0,0) (0,0)
CRYSMEB 0.625 Yes 11,20 1,45 * 7,28
(-8,3) (-56,8) (-11,5)
CRYSMEB 1.25 Yes 10,86 1,73 * 5,53 *
(-11,1) (-48,7) (-32,8)
CRYSMEB 2.5 Yes 11,26 1,13 * 4,82 *
(-7,8) (-66,5) (-41,4)
LOQ (pg/mL) 0,313 0,625 0,625
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated